Myofascial Pain Syndrome (MPS) is a prevalent musculoskeletal disorder characterized by myofascial trigger points (MTrPs) within muscles or fascia. Epidemiological studies suggest a high prevalence of MPS, affecting a significant proportion of individuals with musculoskeletal pain, with peak incidence occurring between ages 27 and 50. While the exact etiology remains elusive, factors such as repetitive microtrauma, musculoskeletal injuries, postural disorders, psychological stress, and hormonal changes are implicated in its development. Pathophysiological mechanisms underlying MPS involve dysfunction of the neuromuscular junction, excessive acetylcholine release, local ischemia, and peripheral and central sensitization. Diagnostic criteria include physical examination findings of palpable taut muscle bands containing MTrPs, hypersensitive nodules, and referred pain patterns. Differential diagnosis involves distinguishing MPS from other soft tissue and spinal disorders. Treatment strategies for MPS are multifaceted, encompassing pharmacological interventions, physical therapy modalities, and MTrP needling techniques. Complications of untreated MPS can impact daily activities and quality of life, underscoring the importance of timely intervention. Understanding MPS’s multifaceted nature is crucial for effective management and improving patients’ quality of life.